Nidufexor
≥99%
- Product Code: 101656
CAS:
1773489-72-7
| Molecular Weight: | 487.93 g./mol | Molecular Formula: | C₂₇H₂₂ClN₃O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
Nidufexor is primarily investigated for its potential therapeutic applications in treating metabolic and liver-related disorders. It acts as a selective agonist for the farnesoid X receptor (FXR), a nuclear receptor involved in regulating bile acid, lipid, and glucose metabolism. This makes it a promising candidate for managing non-alcoholic steatohepatitis (NASH), a condition characterized by liver inflammation and fat accumulation. By modulating FXR activity, it helps reduce liver fat, inflammation, and fibrosis, improving overall liver function. Additionally, it is being explored for its role in improving insulin sensitivity and lipid profiles, which could benefit patients with type 2 diabetes and dyslipidemia. Its ability to regulate metabolic pathways also suggests potential applications in addressing obesity-related complications. Ongoing clinical trials aim to further validate its efficacy and safety in these therapeutic areas.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | $639.13 |
+
-
|
| 0.010 | 10-20 days | $1,065.22 |
+
-
|
Nidufexor
Nidufexor is primarily investigated for its potential therapeutic applications in treating metabolic and liver-related disorders. It acts as a selective agonist for the farnesoid X receptor (FXR), a nuclear receptor involved in regulating bile acid, lipid, and glucose metabolism. This makes it a promising candidate for managing non-alcoholic steatohepatitis (NASH), a condition characterized by liver inflammation and fat accumulation. By modulating FXR activity, it helps reduce liver fat, inflammation, and fibrosis, improving overall liver function. Additionally, it is being explored for its role in improving insulin sensitivity and lipid profiles, which could benefit patients with type 2 diabetes and dyslipidemia. Its ability to regulate metabolic pathways also suggests potential applications in addressing obesity-related complications. Ongoing clinical trials aim to further validate its efficacy and safety in these therapeutic areas.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :